BridgeBio Pharma

BBIO · Nasdaq · United States

Share price · BBIO

$78.01-4.97 (-5.99%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.5M (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BBIO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Oct 2026+6.0%
  2. 9 Jul 2026+15.1%
  3. 10 Mar 2026+13.2%

    Nothing announced by BBIO that day or the session before.

  4. 19 Feb 2026-4.3%

    Nothing announced by BBIO that day or the session before.

  5. 12 Feb 2026+3.7%

    Nothing announced by BBIO that day or the session before.

  6. 9 Feb 2026+6.2%

    Nothing announced by BBIO that day or the session before.

  7. 5 Feb 2026-15.2%

    Nothing announced by BBIO that day or the session before.

  8. 9 Jan 2026+4.6%

    Nothing announced by BBIO that day or the session before.

Share of unusual movement by asset

For each asset, the share of BBIO's own-move activity since 11 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—5%
Sessions with no dated event—95%

No dated announcements about its assets since 11 Nov 2025.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Acoramidis(Attruby)
Approved
Transthyretin (TTR)Small molecule
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Cardiomyopathy

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
April 2028 (1)
Acoramidis · AttrubyPhase 3Amyloid Cardiomyopathy, Transthyretin-Related
Est. primary completion 2028-04-15 · NCT04988386 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Acoramidis · AttrubyPhase 3Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Est. primary completion 2031-10 · NCT06563895 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
Acoramidis · AttrubyPhase 3Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related …
Est. primary completion 2037-11 · NCT07116473 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$353M$144M$1.5B+ $5.5M short-term inv.$57M-$44M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$244M$149M$678M+ $42M short-term inv.$152M-$71M operating cash flowreport ↗
2026-Q1$195M$127M$880M+ $60M short-term inv.$164M-$197M operating cash flowreport ↗
2025-Q3$121M$113M$643M+ $3.0M short-term inv.$183M-$110M operating cash flowreport ↗
2025-Q2$111M$111M$749M+ $7.9M short-term inv.$182M-$81M operating cash flowreport ↗
2025-Q1$117M$111M$541M$167M-$199M operating cash flowreport ↗
2024-Q3$2.7M$120M$266M$162M-$181M operating cash flowreport ↗
2024-Q2$2.2M$115M$408M+ $40M short-term inv.$73M$75M operating cash flowreport ↗
2024-Q1$211M$141M$475M+ $44M short-term inv.$35M-$220M operating cash flowreport ↗
2023-Q3$4.1M$125M$505M+ $0 short-term inv.$177M-$145M operating cash flowreport ↗
2023-Q2$1.6M$107M$302M+ $31M short-term inv.$158M-$113M operating cash flowreport ↗
2023-Q1$1.8M$93M$407M+ $34M short-term inv.$140M-$144M operating cash flowreport ↗
2022-Q3$0.3M$93M$483M+ $75M short-term inv.$137M-$135M operating cash flowreport ↗
2022-Q2$74M$108M$470M+ $218M short-term inv.$9.9M-$30M operating cash flowreport ↗
2022-Q1$1.7M$108M$372M+ $262M short-term inv.$196M-$161M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$502M$452M$570M+ $17M short-term inv.$181M-$446M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$222M$506M$681M+ $0 short-term inv.$134M-$521M operating cash flowreport ↗
2023-FY$9.3M$456M$376M+ $0 short-term inv.$161M-$528M operating cash flowreport ↗
2022-FY$78M$399M$377M+ $52M short-term inv.$120M-$419M operating cash flowreport ↗
2021-FY$70M$451M$394M+ $394M short-term inv.$141M-$498M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 129 sales ($84.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Kumar Neil · director, Chief Executive OfficerOption exercise33,544——Form 4
2026-11-16Apuli Maricel · Chief Accounting OfficerTax withholding4,714$77.36$365KForm 4
2026-11-16Trimarchi Thomas · President and CFOTax withholding22,781$77.36$1.8MForm 4
2026-11-16Kumar Neil · director, Chief Executive OfficerOption exercise19,599——Form 4
2026-11-16Kumar Neil · director, Chief Executive OfficerOption exercise11,554——Form 4
2026-11-16Kumar Neil · director, Chief Executive OfficerOption exercise6,519——Form 4
2026-11-16Kumar Neil · director, Chief Executive OfficerTax withholding36,236$77.36$2.8MForm 4
2026-11-16Kumar Neil · director, Chief Executive OfficerOption exercise (derivative)33,544——Form 4